Cervical Cancer Diagnosis
Cervical Cancer Diagnosis
Cervical cancer is diagnosed in a chain: a screening test raises the question, colposcopy with biopsy answers whether there is precancer or cancer, a cone biopsy resolves disagreement, and MRI with CT or PET-CT establishes how far disease has spread — the last step carrying the stage under FIGO 2018.
Screening result versus diagnosis
A positive HPV test or an abnormal smear is a screening result, not a diagnosis — it says the cervix needs closer looking at, not that cancer is present. The overwhelming majority of abnormal screens resolve as CIN, which is treatable as an outpatient, or as nothing at all. Conversely, a normal screen does not by itself investigate a symptom: bleeding is assessed by examination whatever the last smear said.
Keeping the two tracks separate matters, because they answer different questions and run at different speeds. Screening asks who should be examined more closely and can wait its scheduled interval; the diagnostic track asks what is this lesion and moves within weeks. Women who mix them up — repeating a screening test instead of attending colposcopy, or assuming a recent screen covers a new symptom — lose the most time.
Colposcopy and biopsy
Colposcopy is the examination that turns a screening result into a diagnosis. The cervix is viewed under magnification after acetic acid (and sometimes iodine) is applied, which makes abnormal epithelium appear white and fail to stain where normal tissue darkens. The patterns direct where biopsies are taken — small punches of tissue from the most abnormal-looking areas, taken as an outpatient procedure with little more than brief cramping.
Two refinements matter in practice. An endocervical curettage samples cells from inside the canal when the transformation zone sits too high to see — relevant for adenocarcinoma, which arises in the canal. And the biopsy is what diagnoses: colposcopy decides where to sample, but the pathologist's report on the sample decides what the lesion is, which is why a biopsy is always taken before treatment is discussed.
Diagnostic conization
A cone biopsy — removing a cone-shaped cylinder of cervical tissue, by LEEP (a wire loop with electrical current) or by cold knife — serves both diagnosis and, for small lesions, treatment. It is requested when colposcopy and biopsy do not agree with the cytology, when the biopsy shows changes that may be more severe higher in the canal, when the canal cannot be assessed, and whenever the exact depth of invasion is needed to stage a suspected early cancer.
The specimen answers questions a punch biopsy cannot: how deep the invasion reaches into the cervical wall, how wide it is, and whether the margins are clear. Those three numbers are what decide between a cone as complete treatment and a further operation — which is why conization is done as a precise, measured procedure rather than an expedient one, and why the depth and margin findings should be in any file sent for a second opinion.
MRI, CT and PET-CT
Imaging does for this cancer what it does for no other gynaecological cancer: it is written into the staging system itself. Pelvic MRI is the reference test for measuring the tumour, seeing whether it has grown into the parametrium beside the cervix, and assessing the upper vagina and the canal — its measurements directly determine whether a tumour is IB1, IB2 or IB3, and therefore whether fertility-sparing surgery is even on the table.
CT and PET-CT stage the rest: the pelvic and para-aortic nodes, and distant organs. PET-CT is particularly useful for nodes that look normal in size but behave abnormally, which changes the radiotherapy field. Cystoscopy or sigmoidoscopy is added where bladder or rectal involvement is suspected on MRI. The sequence — MRI first, then PET-CT where nodes matter — is worth keeping, because the MRI finding is what decides whether nodal imaging changes anything.
FIGO 2018 staging
Since 2018, FIGO staging for cervical cancer permits imaging and pathology findings — a change with real consequences. Under the old rules a small tumour with involved nodes was staged as if the nodes were not there; under FIGO 2018 it is stage IIIC, which moves the plan from surgery to chemoradiotherapy. The stage also records how the information was obtained, with the suffix distinguishing imaging from pathology.
The stages that drive treatment are: IA1 (microscopic invasion ≤3 mm), IB1 (≤2 cm confined to the cervix), IB2–IB3 (2–4 cm and above 4 cm), IIA (upper vagina, no parametrium), IIB (parametrium involved), IIIC (pelvic nodes IIIC1, para-aortic IIIC2), IVA (bladder or rectal lining invaded) and IVB (distant spread). The full table with treatment implications is on the overview page.
Bringing it into one plan
Diagnosis in this disease is not complete until four documents exist: the pathology report (type, depth of invasion, margins), the MRI report with the measured tumour size and parametrial status, the nodal assessment from CT or PET-CT, and the FIGO stage derived from them. A plan built on the biopsy alone misses exactly the findings — parametrial spread, involved nodes — that redirect treatment from surgery to radiotherapy.
For international patients, the practical translation: send the pathology and the imaging discs, not summaries of them. Where records are incomplete, the missing piece is usually the MRI, because it is the measurement on which the stage — and therefore the choice between operation and chemoradiotherapy — turns. Once the file is complete, a gynaecological oncology MDT can state the route within 48 hours.